Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in combination with Cyclophosphamide, Doxorubicin, and Prednisone in patients with Anaplastic Large Cell Lymphoma.

Statements

Source and description
Adcetris (brentuximab vedotin) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Adcetris (brentuximab vedotin) [product monograph]. HC. Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.